P940: An outpatient model for teclistamab step-up dosing administration – Initial experiences at Fox Chase Cancer Center BMT program

This abstract described the results of an evaluation of the safety and feasibility of the outpatient teclistamab administration model with close toxicity monitoring and prompt hospitalization for toxicity management. It was found to be safe and feasible in patients with heavily pre-treated relapsed/refractory multiple myeloma and allowed for a significant reduction of inpatient stay and its associated cost.